Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38521086

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2024 Apr 6
First author
Lorusso D

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2024 Apr 6;403(10434):1310-1311. doi: 10.1016/S0140-6736(24)00468-9.
    note
    Source null
    related pmid
    38521084
    relationship
    Comment in

Authors and identifiers

  1. name
    Lorusso D
    type
    Author
  2. name
    Xiang Y
    type
    Author
  3. name
    Hasegawa K
    type
    Author
  4. name
    Scambia G
    type
    Author
  5. name
    Leiva M
    type
    Author
  6. name
    Ramos-Elias P
    type
    Author
  7. name
    Acevedo A
    type
    Author
  8. name
    Sukhin V
    type
    Author
  9. name
    Cloven N
    type
    Author
  10. name
    Pereira de Santana Gomes AJ
    type
    Author
  11. name
    Contreras Mejía F
    type
    Author
  12. name
    Reiss A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Lorusso D
    type
    Author
  2. name
    Xiang Y
    type
    Author
  3. name
    Hasegawa K
    type
    Author
  4. name
    Scambia G
    type
    Author
  5. name
    Leiva M
    type
    Author
  6. name
    Ramos-Elias P
    type
    Author
  7. name
    Acevedo A
    type
    Author
  8. name
    Sukhin V
    type
    Author
  9. name
    Cloven N
    type
    Author
  10. name
    Pereira de Santana Gomes AJ
    type
    Author
  11. name
    Contreras Mejía F
    type
    Author
  12. name
    Reiss A
    type
    Author
bibliography ids
  1. nci-bib-fc897b96a30a285c03add56f
book metadata
content sha256
fb16a06b7a4f01ecdf7b0077468dfb3351f263ec8de1efc652547b522e3d7816
document type
citation
dois
  1. 10.1016/S0140-6736(24)00317-9
electronic publication date
display
2024 Mar 20
precision
day
year
2024
evidence scope
bibliographic_metadata_only
id
pubmed:38521086
immutable id
pubmed:38521086@fb16a06b7a4f01ecdf7b0077468dfb3351f263ec8de1efc652547b522e3d7816
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10434
name
Lancet (London, England)
nlm unique id
2985213R
pages
1341-1350
volume
403
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2024 Apr 6;403(10434):1310-1311. doi: 10.1016/S0140-6736(24)00468-9.
    note
    Source null
    related pmid
    38521084
    relationship
    Comment in
outcomes validated
false
pmid
38521086
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
c5586c2c129f3cacdf82b4e1c9920149ebd33dfbc4075572391c0b8dd8106480
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2024 Apr 6
precision
day
year
2024
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38521086/
title
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.

Preserved source evidence · Not medical advice